clinical trials

News

AstraZeneca has had a setback in its oncology pipeline, as AKT inhibitor ceralasertib fails to improve survival in a phase 3 lung cancer trial.

R&D

We round up the key data and innovations in Q4 2025 - and what these likely presage for 2026’s R&D focus.

R&D

Eloise McLennan looks at a set of signals areas where pressure is building and 2026 looks set to demand more clarity, discipline, and follow-through.

R&D

An emerging consensus across sponsors, investigators, and regulators is that agility must become a defining attribute of CRO performance.

News

Lilly breaks new ground for oral GLP-1 agonists with data showing it can help patients keep weight off after treatment with injectable therapies.

News

Takeda intends to file for approval of its oral psoriasis therapy zasocitinib next year, with Bristol Myers Squibb's Sotyktu in its sights.